Zhongshan Zhiben Pharmaceutical Technology Co, a company in Cuiheng New District, announced that ZB-001, a new antibacterial drug co-developed by the company with the Shanghai Institute of Materia Medica, has been approved for clinical trials by the Center for Drug Evaluation.

ZB-001 is intended for the treatment of simple gonorrhea and other bacterial infections. It is expected to provide a new solution to bacterial resistance (gonococcus, staphylococcus aureus, etc).

Established in 2021 with the support of SIMM and the Zhongshan Institute for Drug Discovery, Zhiben focuses on the research and development of small molecule innovative drugs.

From 2023, Cuiheng New District will earmark 50 million yuan every year to support 10-20 start-up innovative drug R&D teams.